Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir prophylaxis versus pre-emptive therapy after kidney transplantation
ACTRN12613000554763Phase 4Completed
- Sponsor
- Tomas Reischig
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Tomas Reischig. Primary endpoints: Acute rejection diagnosed by renal allograft biopsy and Moderate-to-severe interstitial fibrosis/tubular atrophy in protocol biopsy. Started Jun 2013; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ACTRN12613000554763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000554763.